Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
DYN Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 14, 2026
Report Source: 2026 1st Quarter Report
Dyne Therapeutics, Inc. Stock Analysis DYN
United States Health Care Mid Cap Report: Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.
Read More Dyne Therapeutics, Inc (DYN) Chart
Key Statistics of Dyne Therapeutics, Inc (DYN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$20.44Volume
2.08MP/E Ratio (TTM)
-52 Week Range
Market Cap
2.87BAvg. Volume
1.88MDividend Yield
-Financial Metrics & Statements of Dyne Therapeutics, Inc (DYN)
FAQ's for Dyne Therapeutics, Inc (DYN)
- According to Musaffa’s Shariah screening methodology, Dyne Therapeutics, Inc (DYN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Dyne Therapeutics, Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Dyne Therapeutics, Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Dyne Therapeutics, Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Dyne Therapeutics, Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Dyne Therapeutics, Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.